Powered by

Gilead's Kite taps Teneobio to build next-gen CAR-Ts for multiple myeloma

Apr 02, 2020 - FierceBiotech

Although front-line treatments for multiple myeloma work well for most patients, many of them eventually relapse, running out of drugs to treat their cancer. Gilead Sciences' Kite Pharma is working on new CAR-T therapies for these patients—and it's enlisted Teneobio's antibody technology to do so.

Although front-line treatments for multiple myeloma work well for most patients, many of them eventually relapse, running out of drugs to treat their cancer. Gilead Sciences' Kite Pharma is wo...